SK Biopharm, Supply Agreement for Senobamate Sales in the United States

[Asia Economy Reporter Hwang Junho] SK Biopharm announced on the 22nd that it has signed a product supply contract worth 14.3155 billion KRW with SK Life Science, Inc., SK Biopharm's local subsidiary in the United States, for the sale of the new epilepsy treatment drug Cenobamate (product name: XCOPRI®) in the U.S. market. The contract period will run from today until February 28 of next year.